SCHEMBL12087699

SCHEMBL12087699

CCN1CCc2ccccc2NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.49
▸ CREBBP Q92793 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ MAPK13 O15264 1/20 0.49
▸ MAPK12 P53778 1/20 0.49
▸ MAPK11 Q15759 1/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ MAPT P10636 2/20 0.46
▸ AHR P35869 1/20 0.42
▸ PDK2 Q15119 1/20 0.42
▸ DDB1 Q16531 2/20 0.41
▸ CRBN Q96SW2 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10668472 0.83 BRD4 (0.61) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL30970866 0.83 BRD4 (0.61) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL2606232 0.77 BRD4 (0.68) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL12231865 0.75 BRD4 (0.44) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL12252977 0.75 CRBN (0.43) DDB1CRBN
SCHEMBL12253555 0.75 BRD4 (0.44) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL13068201 0.74 BRD4 (0.43) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL13907678 0.74 NPC1 (0.53) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL2603742 0.73 BRD4 (0.49) BRD4CREBBPNPC1MAPK13MAPK12
SCHEMBL828845 0.73 BRD4 (0.49) BRD4CREBBPNPC1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748429-B2 CGRP receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-10 — — US disclosed
EP-2271640-B1 Piperidine derivatives as CGRP receptor antagonists BRISTOL MYERS SQUIBB CO (US) 2012-09-05 — — EP disclosed
US-20070238715-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238715-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA BRD4 3351/4885CREBBP 1628/4885NPC1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback